Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares View HTML
Toggle Summary Flexion Therapeutics Announces Pricing of Initial Public Offering View HTML
Toggle Summary Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering View HTML
Toggle Summary Flexion Therapeutics Presents Robust Phase 2b Data for FX006 at 2013 American College of Rheumatology Annual Scientific Meeting
– In a clinical trial, a single-dose of 40 mg of FX006 demonstrated enhanced therapeutic effects relative to the approved injectable dose of commonly available, immediate release steroid in patients with osteoarthritis of the knee –
View HTML
Toggle Summary Flexion Therapeutics to Present Phase 2b Data for FX006 at 2013 American College of Rheumatology Annual Scientific Meeting
– Oral presentation at ACR will highlight results from first head-to-head dose-ranging study comparing FX006 with approved injectable dose of commonly prescribed, immediate release steroid for patients with osteoarthritis (OA) of the knee –
View HTML
Toggle Summary Flexion’s FX006 Demonstrates Superior Pain Relief Compared to Standard-of-Care in Phase 2b Osteoarthritis Trial
– FX006 Provides Pain Relief Signal That is Among the Largest Seen in Osteoarthritis Clinical Trials – – Optimal Dose for Phase 3 Trial Identified –
View HTML
Toggle Summary Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer View HTML
Toggle Summary Data Presented at OARSI’s 2013 World Congress on Osteoarthritis Show Flexion’s FX006 Has Prolonged Therapeutic Concentration in Knee Joint View HTML
Toggle Summary Flexion Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference View HTML
Toggle Summary Flexion's FX006 Achieves Prolonged Therapeutic Concentrations in Joints of Osteoarthritis Patients View HTML